3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
5
Endocrine
2
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
17
Fallopian Tube Neoplasms
6
Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Sarcoma
2
Recurrence
2
Pancreatic Neoplasms
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Diseases
1
Uterine Cervical Diseases
1
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrent Uterine Corpus Sarcoma
1
Prostatic Neoplasms
1
Hypertension
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
5
Magnetic Resonance Spectroscopy
4
Trastuzumab
3
Nivolumab
3
ulixertinib
2
palbociclib
2
lenvatinib
2
belinostat
2
Sunitinib
2
Specimen Handling
2
Fluorodeoxyglucose F18
2
FAPI-46
2
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
tipifarnib
1
spartalizumab
1
sargramostim
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pazopanib
1
osimertinib
1
omipalisib
1
olaparib
1
methyl N-acetylsibirosaminide
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
pazopanib
×
Gynecologic
×
Clear all
NCT05949424
2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4
Unknown
30 enrolled